SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM, et al. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum 2007; 57: 83744.
  • 2
    Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999; 42: 7809.
  • 3
    Aouba A, Pagnoux C, Bienvenu B, Mahr A, Guillevin L. Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects. Clin Rev Allergy Immunol 2008; 34: 6573.
  • 4
    Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assoc J 2002; 4: 10068.
  • 5
    Teichmann LL, Woenckhaus M, Vogel C, Salzberger B, Scholmerich J, Fleck M. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 12567.
  • 6
    Godeau B, Coutant-Perronne V, Le Thi Huong D, Guillevin L, Magadur G, De Bandt M, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994; 21: 24651.
  • 7
    Ognibene FP, Shelhamer JH, Hoffman GS, Kerr GS, Reda D, Fauci AS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995; 151: 7959.
  • 8
    Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007; 3: CD005590.
  • 9
    Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al, and the European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 3107.
  • 10
    Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007; 82: 10529.
  • 11
    Marcotte H, Levesque D, Delanay K, Bourgeault A, de la Durantaye R, Brochu S, et al. Pneumocystis carinii infection in transgenic B cell-deficient mice. J Infect Dis 1996; 173: 10347.
  • 12
    Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 2006; 176: 614754.
  • 13
    Lund FE, Schuer K, Hollifield M, Randall TD, Garvy BA. Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific antibody. J Immunol 2003; 171: 142330.
  • 14
    Dittrich AM, Schulze I, Magdorf K, Wahn V, Wahn U. X-linked agammaglobulinaemia and Pneumocystis carinii pneumonia: an unusual coincidence? [letter]. Eur J Pediatr 2003; 162: 4323.
  • 15
    Wilk E, Witte T, Marquardt N, Horvath T, Kalippke K, Scholz K, et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum 2009; 60: 356371.